China NMPA Pharmaceutical Packaging Registration & CDE Joint Review
Guiding domestic and foreign packaging firms through China CDE registrations, dossier drafting, obtaining codes, and responding to CDE deficiency loops.
China NMPA applies a joint review system for packaging. Suppliers register dossiers on the CDE portal, obtaining a code showing as "I" (Inactive). When a drug buyer files their formulation, the CDE co-evaluates the packaging. Upon approval, the packaging status changes to "A" (Active) in the database, authorizing commercial supply.
Key Modules in CDE Packaging Dossiers
Submissions must comply with CDE specifications, focusing on physical quality uniformity and ingredient supplier audits.
- Formulation: disclosing the source, grade, and percentage of resins and deliberate additives
- Manufacturing: clarifying extrusion, blowing, or injection molding steps, parameters, and specifications
- Specifications: detailing design schematics, wall thickness controls, gas/moisture transmission rates
FAQ
Must imported packaging register on China CDE?+
Yes. If imported drugs utilize packaging made abroad, the foreign supplier (appointing a Chinese agent) must file with CDE to obtain a registration code, or the drug importer cannot complete joint review link.
Next steps
If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.
